Holen Sie sich die Stockscreener-App
55.49
1.28%
0.70
Handel nachbörslich:
54.52
-0.97
-1.75%
Schlusskurs vom Vortag:
$54.79
Offen:
$54.83
24-Stunden-Volumen:
3.26M
Relative Volume:
1.35
Marktkapitalisierung:
$10.61B
Einnahmen:
$217.77M
Nettoeinkommen (Verlust:
$-438.86M
KGV:
-23.02
EPS:
-2.41
Netto-Cashflow:
$-456.33M
1W Leistung:
+4.98%
1M Leistung:
+4.78%
6M Leistung:
+71.74%
1J Leistung:
+122.32%
1-Tages-Spanne:
$54.66
$55.94
1-Wochen-Bereich:
$52.97
$55.94
52-Wochen-Spanne:
$21.72
$55.94
Bridgebio Pharma Inc Stock (BBIO) Company Profile
Firmenname
Bridgebio Pharma Inc
Sektor
Branche
Telefon
(650) 391-9740
Adresse
3160 PORTER DR., PALO ALTO, CA
Vergleichen Sie BBIO mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
BBIO
Bridgebio Pharma Inc
|
55.49 | 10.47B | 217.77M | -438.86M | -456.33M | -2.41 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Bridgebio Pharma Inc Stock (BBIO) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-30 | Fortgesetzt | Raymond James | Outperform |
| 2025-07-21 | Eingeleitet | Truist | Buy |
| 2025-07-14 | Eingeleitet | Jefferies | Buy |
| 2025-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2025-06-17 | Eingeleitet | Wolfe Research | Outperform |
| 2025-03-31 | Eingeleitet | Redburn Atlantic | Buy |
| 2024-10-16 | Eingeleitet | Scotiabank | Sector Outperform |
| 2024-10-03 | Eingeleitet | Oppenheimer | Perform |
| 2024-09-04 | Eingeleitet | Piper Sandler | Overweight |
| 2024-03-21 | Fortgesetzt | Raymond James | Outperform |
| 2024-01-31 | Eingeleitet | BMO Capital Markets | Market Perform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-11-07 | Eingeleitet | Citigroup | Buy |
| 2023-10-24 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-07-18 | Herabstufung | Jefferies | Buy → Hold |
| 2023-04-19 | Eingeleitet | Evercore ISI | Outperform |
| 2023-02-06 | Eingeleitet | Cowen | Outperform |
| 2021-12-27 | Bestätigt | Mizuho | Buy |
| 2021-12-27 | Bestätigt | SVB Leerink | Outperform |
| 2021-09-10 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-05-21 | Eingeleitet | UBS | Buy |
| 2021-03-22 | Bestätigt | Goldman | Buy |
| 2021-02-22 | Fortgesetzt | JP Morgan | Overweight |
| 2021-02-09 | Fortgesetzt | Goldman | Buy |
| 2021-01-11 | Bestätigt | H.C. Wainwright | Buy |
| 2020-12-10 | Bestätigt | H.C. Wainwright | Buy |
| 2020-06-25 | Eingeleitet | BofA/Merrill | Neutral |
| 2020-05-19 | Eingeleitet | BTIG Research | Buy |
| 2020-04-13 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-02-19 | Eingeleitet | Mizuho | Buy |
| 2019-07-26 | Eingeleitet | Raymond James | Outperform |
| 2019-07-22 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-07-22 | Eingeleitet | Goldman | Buy |
| 2019-07-22 | Eingeleitet | JP Morgan | Overweight |
| 2019-07-22 | Eingeleitet | Jefferies | Buy |
| 2019-07-22 | Eingeleitet | Piper Jaffray | Overweight |
| 2019-07-22 | Eingeleitet | SVB Leerink | Outperform |
Alle ansehen
Bridgebio Pharma Inc Aktie (BBIO) Neueste Nachrichten
BridgeBio (BBIO) Leads Biotech Sector with Promising Pipeline - GuruFocus
SA Asks: What's the most attractive biotech stock right now? - Seeking Alpha
Oak Ridge Investments LLC Purchases New Holdings in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Published on: 2025-10-12 03:32:49 - newser.com
BridgeBio Pharma (NASDAQ:BBIO) CEO Neil Kumar Sells 40,000 Shares - MarketBeat
Using flow based indicators on BridgeBio Pharma Inc.2025 Analyst Calls & Consistent Profit Trading Strategies - newser.com
Sentiment analysis tools applied to BridgeBio Pharma Inc.2025 Price Targets & Weekly High Return Opportunities - newser.com
Why BridgeBio Pharma Inc. (2CL) stock could outperform next yearJuly 2025 Breakouts & AI Based Trade Execution Alerts - newser.com
Will BridgeBio Pharma Inc. bounce back from current supportWeekly Risk Summary & Safe Entry Momentum Stock Tips - newser.com
BridgeBio Pharma (NASDAQ:BBIO) Given Sell (D-) Rating at Weiss Ratings - MarketBeat
BridgeBio Pharma Hits New 52-Week High of $55.33, Up 98.71% - Markets Mojo
Using economic indicators to assess BridgeBio Pharma Inc. potentialJuly 2025 Intraday Action & Daily Chart Pattern Signals - newser.com
Leading vs lagging indicators on BridgeBio Pharma Inc. performance2025 Momentum Check & Free Fast Entry Momentum Trade Alerts - newser.com
Real time breakdown of BridgeBio Pharma Inc. stock performanceIPO Watch & Risk Managed Investment Signals - newser.com
Will breakout in BridgeBio Pharma Inc. lead to full recoveryJuly 2025 Intraday Action & Growth Focused Entry Point Reports - newser.com
BridgeBio Pharma Hits New 52-Week High of $55.13, Up 94.83% - Markets Mojo
BridgeBio Pharma, Inc. Experiences Revision in Stock Evaluation Amid Strong Market Performance - Markets Mojo
BridgeBio Pharma Hits New 52-Week High of $54.64, Up 96.23% - Markets Mojo
BridgeBio Pharma (NASDAQ:BBIO) Sets New 12-Month HighHere's What Happened - MarketBeat
BridgeBio Pharma stock hits 52-week high at $54.61 By Investing.com - Investing.com South Africa
BridgeBio Pharma stock hits 52-week high at $54.61 - Investing.com
Analyzing drawdowns of BridgeBio Pharma Inc. with statistical toolsJuly 2025 Decliners & Fast Gaining Stock Strategy Reports - newser.com
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(4) - MarketScreener
How buybacks impact BridgeBio Pharma Inc. stock valueGap Up & Growth Focused Stock Reports - newser.com
PFG Investments LLC Takes Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
What MACD and RSI say about BridgeBio Pharma Inc.Weekly Market Outlook & Target Return Focused Stock Picks - newser.com
Pattern recognition hints at BridgeBio Pharma Inc. upsideJuly 2025 EndofMonth & Pattern Based Trade Signal System - newser.com
BridgeBio Pharma (BBIO) Is Up 5.6% After Acoramidis Shows Broad ATTR-CM Benefit in Phase 3 Data - Yahoo
BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire
BridgeBio Pharma reports inducement grants under Nasdaq Listing Rule - MarketScreener
23,884 RSUs: BridgeBio Grants Inducement Shares with Quarterly Vesting Starting Nov. 16, 2026 - Stock Titan
What earnings revisions data tells us about BridgeBio Pharma Inc.2025 Geopolitical Influence & Daily Risk Controlled Trade Plans - newser.com
How big funds are accumulating BridgeBio Pharma Inc. (2CL) stockJuly 2025 Summary & Low Drawdown Trading Strategies - newser.com
UBS Reaffirms Buy on BridgeBio (BBIO) With Optimism Around Attruby Launch - Yahoo Finance
BridgeBio Pharma, Inc. (BBIO) Retains $68 Target on Strong Launch Dynamics - MSN
Platinum Investment Management Ltd. Grows Position in BridgeBio Pharma, Inc. $BBIO - MarketBeat
Hypoparathyroidism Market to Experience Notable Growth in Forecast Span by 2034, DelveInsight Predicts | Bridgebio/Calcil ytix Therapeutics, Ascendis Pharma, EnteraBio, Shire - Barchart.com
7 Most Promising Biotech Stocks to Buy According to Hedge Funds - Insider Monkey
Finanzdaten der Bridgebio Pharma Inc-Aktie (BBIO)
Umsatz
Nettogewinn
Free Cashflow
ENV
Bridgebio Pharma Inc-Aktie (BBIO) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Kumar Neil | Chief Executive Officer |
Oct 08 '25 |
Sale |
54.78 |
40,000 |
2,191,350 |
855,686 |
5.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):